Assessing the performance of CROs
Assessing the performance of CROs
Pharmaceutical and biotech companies want to speed up the research and development process whilst adhering to stricter guidelines. That’s why CRO’s are primarily selected on their scientific expertise and the cost/value ratio.
If R&D companies have always had a ‘feeling’ about their CRO, they are now more and more looking for facts in assessing their performance. This can only be done by “Choosing the right metrics” and “Deploying the right tools to evaluate these metrics”. Read more
No commentsNon-exhaustive listing of clinical trial performance metrics initiatives
Since we started, with Evidence, to talk about performance metrics in the clinical environment, I’m trying to obtain a clear picture of the active actors in this domain of expertise.
After few months, it becomes clear to me that it is not so easy to obtain this picture perhaps because we are facing a really emerging market with very few initiatives so far. Nevertheless, I think that this type of information could be very valuable for everyone in the community who shares our interest in this matter.
No commentsClinical Trial Performance - why should we assess it?
Have you ever been asked to “reduce the costs to develop new pharmaceutical products and / or to reduce time to market”? Yes? Then you will be interested in sharing your experience and ideas on this matter!
No comments
